Financial Survey: Spectrum Pharmaceuticals (SPPI) versus Its Competitors
Spectrum Pharmaceuticals (NASDAQ: SPPI) is one of 190 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Spectrum Pharmaceuticals to related businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.
This table compares Spectrum Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Spectrum Pharmaceuticals Competitors||-3,369.14%||-98.75%||-39.73%|
Valuation & Earnings
This table compares Spectrum Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Spectrum Pharmaceuticals||$146.44 million||-$68.51 million||-19.70|
|Spectrum Pharmaceuticals Competitors||$213.24 million||-$39.02 million||-64.68|
Spectrum Pharmaceuticals’ competitors have higher revenue and earnings than Spectrum Pharmaceuticals. Spectrum Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of recent recommendations for Spectrum Pharmaceuticals and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Spectrum Pharmaceuticals Competitors||510||2428||6598||122||2.66|
Spectrum Pharmaceuticals presently has a consensus price target of $24.25, suggesting a potential upside of 24.36%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 16.01%. Given Spectrum Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Spectrum Pharmaceuticals is more favorable than its competitors.
Risk & Volatility
Spectrum Pharmaceuticals has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Comparatively, Spectrum Pharmaceuticals’ competitors have a beta of 1.52, indicating that their average stock price is 52% more volatile than the S&P 500.
Insider & Institutional Ownership
58.5% of Spectrum Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.3% of Spectrum Pharmaceuticals shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Spectrum Pharmaceuticals beats its competitors on 8 of the 12 factors compared.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.
Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.